



CSD/SE/2024-25
January 24, 2025

To
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

**Sub: Statement of Deviation(s) or variation(s) for quarter ended 31st December, 2024
under Regulation 32 of SEBI (LODR) Regulations, 2015**

.....

With reference to the above subject, please find enclosed statement confirming that there were **no deviation(s) or variation(s) in the use of proceeds**, from the objects for which funds were raised through the Rights Issue made by the Company, for the quarter ended 31st December, 2024.

We request you to take this on your record.

Thanking you.

Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Company Secretary

Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Statement of Deviation / Variation in utilisation of funds raised						
Name of listed entity	Suven Life Sciences Limited					
Mode of Fund Raising	Rights Issue					
Date of Raising Funds (Allotment)	16/11/2022					
Total Amount Raised (in Rs. crores)	Rs. 399.80 Crores.					
Report filed for Quarter ended	31 December, 2024					
Monitoring Agency	Applicable					
Monitoring Agency Name, if applicable	CRISIL Ratings Limited					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable					
If Yes, Date of shareholder Approval	Not Applicable					
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	Nil					
Comments of the auditors, if any	Not Applicable					
Objects for which funds have been raised and where there has been a deviation, in the following table	As mentioned below					
Original Object	Modified Object, if any	Original Allocation (A)	Modified allocation, if any	Funds Utilized (B)	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
Meeting costs related to pharmaceutical research and development and clinical trial for molecules in the research pipelines	Not Applicable	Rs. 250.01 Crore	Not Applicable	Rs. 250.01 Crore	Not Applicable	The allocated amount fully utilized towards the said object during the quarter ended 31/12/2024.

Repayment of Inter-corporate deposit availed by Company	Not Applicable	Rs. 50.00 Crore	Not Applicable	50.00 Crore	Not Applicable	The allocated amount was fully utilized towards the said object during the quarter ended 31/12/2022.
General corporate purpose #	Not Applicable	Rs. 96.99 Crore	Not Applicable	Rs. 74.89 Crore	Not Applicable	The difference amount (A-B) of Rs. 22.10 Crore is yet to be utilized as on 31/12/2024.

Note: The Letter of Offer dated October 18, 2022, specifies that:

"In the event that there is a shortfall of funds required for research and development activities and conducting such clinical trials projects then, such shortfall shall be met out of the amounts allocated for General Corporate Purpose and/or through internal accruals." Pursuant to aforementioned disclosure, the Company has utilized the net proceeds in following manner:

Particulars	Rs. in Lakhs
Balance available for utilization towards Object 1 as at the beginning of the quarter	437.95
Proceeds utilized during the quarter for Object 1	3638.61
Shortfall met out of General Corporate Purpose*	3200.66

*The above mentioned adjustment is in line with the terms & conditions set forth in the Letter of Offer.

Deviation or variation could mean:

(a) *Deviation in the objects or purposes for which the funds have been raised or*

(b) *Deviation in the amount of funds actually utilized as against what was originally disclosed or*

(c) *Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc*

For Suvan Life Sciences Limited

M. Mohan Kumar

M. Mohan Kumar
Chief Financial Officer

